

A
Rat IgG2b control
9F8BO Anti-Olfml3B
46A9BO Anti-Olfml3B



B
Tumor weight (mg)
120
100
80
60
40
20
0
*
*
Rat IgG2b Control
9F8BO Anti-Olfml3B
46A9BO Anti-Olfml3B

FIG. 1



D0
S.C. LLC1
D5
α treatment
D7
α treatment
D9
α treatment
D11
sacrifice
Total rat IgG
46A9 30 ug
46A9 150 ug
46A9 750 ug
Tumor Volume (mm³)
Days
0
20
40
60
80
5
6
7
8
9
10
11
ns/30
ns/150
ns/750
*/150
**/750
****/30
****/150
****/750
**/30
**/150
**/750

FIG. 2



START
D0
s.c. LLC1
D5
mAb treatment
D7
mAb treatment
D9
mAb treatment
D11
sacrifice
150 µg / mouse
mAb 1: 9F8
mAb 2: 46A9
Tumor Volume (mm³)
150
100
50
0
5
6
7
8
9
10
11
Days
Isotype control
mAb 1
mAb 2

FIG. 3




FIG. 4A



α-SMA+ area
(% of control)
120
100
80
60
40
20
0
11G8
mAb 1
mAb 2
**
**
α-SMA+ pericyte coverage
(% of control)
120
100
80
60
40
20
0
11G8
mAb 1
mAb 2
*
0.0656

FIG. 4B



4GA9
4GA9 deglyc.
OD
µg/ml
0
0.037
0.111
0.33
1
3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1

FIG. 5